Your Research
Deserves a Writer Who Reads the
Methods Section First.
Manuscripts polished to Nature standards. Regulatory narratives that move FDA reviewers. Literature reviews woven from hundreds of citations into a single compelling thread.
Free Resource
Download the Science Writing Brief Template
No spam. Unsubscribe at any time.
Science writing is not copywriting. Here's the difference.
A copywriter sells the product. A science writer is the product — the invisible intelligence that makes your data legible to a journal editor reviewing 400 submissions this week, or an FDA reviewer cross-referencing your safety narrative against three previous 510(k) clearances.
The difference shows in the second paragraph of your introduction: does it demonstrate you've read the methods sections of your 40 cited papers, or does it feel assembled from abstracts? Reviewers know. Grant panels know. We know.
"What makes a manuscript publishable in Nature isn't the data. It's the argument. Your data is already extraordinary — you need someone who can build the case."
Dr. Priya Venkataraman
Neuroscientist · Nature Neuroscience, 2024
What a developmental edit actually changes
Structure, argument architecture, the logical thread from hypothesis to conclusion. Not grammar — the bones. A developmental edit on a 6,000-word manuscript typically takes 3 working days and produces a marked-up document plus a 2-page editorial memo.
Why FDA narratives fail (and how to fix them)
Most 510(k) submissions fail not on the science but on narrative clarity. Reviewers need to follow your argument without re-reading. That requires a writer who understands predicate devices, substantial equivalence, and how to frame a safety profile.
Weaving 200 citations into one argument
A literature review isn't an annotated bibliography. It's a curated argument about the state of a field. We read primary sources, not just abstracts, and build a synthesis that positions your contribution with surgical precision.
What we write. And how.
From raw data to first-author submission
Argument architecture, figure legends that tell the story, discussion sections that land without overselling. 5–10 business days for a full manuscript developmental edit.
FDA narratives that move reviewers
510(k) · De Novo · PMA · IND · NDA
200 citations.
One argument.
Primary-source synthesis, not abstract aggregation. We read the methods sections.
Breakthroughs for the public imagination
Lay summaries, press releases, university comms.
"The manuscript came back restructured in a way I hadn't imagined — the argument was cleaner, the narrative arc was there. It went out to Nature Neuroscience and cleared peer review on the first round. I've never had that happen before."
Dr. Priya Venkataraman
Postdoctoral Fellow, Stanford Neurosciences
Nature Neuroscience · 2024
A first-round acceptance at a top-tier journal is statistically rare. What separates submissions isn't usually the science — it's the clarity of the argument, the precision of the framing, and whether the reviewer can follow your logic without having to re-read your introduction.
On manuscript development
Regulatory writing is a genre with its own grammar. The FDA reviewer reading your 510(k) has seen 300 submissions this quarter. Your narrative needs to be so clear, so logically structured, that they can follow your substantial equivalence argument without a second read-through.
On regulatory narrative
"I gave them a spreadsheet of 240 citations and a rough outline. What came back was a literature review that three of my colleagues asked to use in their own grant applications. It was that good."
Prof. Sandra Okonkwo
Chair, Department of Molecular Biology, UPenn
NIH R01 Grant Application · 2025
Local collaboration or fully remote. Your call.
We work with research institutions across the US. In major research hubs, we offer in-person manuscript workshops. Everywhere else, our remote collaboration is indistinguishable — same turnaround, same depth of engagement.
Check Your Area
Enter your city or ZIP code to see local collaboration options, turnaround benchmarks, and nearby institutional clients.